BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) stock jumped 1.88% on Friday to $14.64 against a previous-day closing price of $14.37. With 2.78 million shares changed hands, the volume of the stock remained lighter than its average volume of 3.25 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $14.86 whereas the lowest price it dropped to was $14.44. The 52-week range on BCRX shows that it touched its highest point at $19.99 and its lowest point at $7.61 during that stretch. It currently has a 1-year price target of $18.60. Beta for the stock currently stands at 2.21.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of BCRX was up-trending over the past week, with a rise of 4.20%, but this was up by 27.42% over a month. Three-month performance surged to 85.55% while six-month performance fell -18.17%. The stock lost -12.02% in the past year, while it has gained 5.70% so far this year. A look at the trailing 12-month EPS for BCRX yields -1.14 with Next year EPS estimates of -0.79. For the next quarter, that number is -0.28. This implies an EPS growth rate of 6.00% for this year and 40.80% for next year. EPS is expected to grow by 15.20% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -6.60%.
Float and Shares Shorts:
At present, 185.60 million BCRX shares are outstanding with a float of 184.15 million shares on hand for trading. On Jul 14, 2022, short shares totaled 31.46 million, which was 16.95% higher than short shares on Jun 14, 2022. In addition to Mr. Jon P. Stonehouse as the firm’s CEO, Pres & Exec. Director, Mr. Anthony J. Doyle serves as its Sr. VP & CFO.
Through their ownership of 73.40% of BCRX’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 36.08% of BCRX, in contrast to 31.77% held by mutual funds. Shares owned by individuals account for 12.51%. As the largest shareholder in BCRX with 7.21% of the stake, The Vanguard Group, Inc. holds 13,381,055 shares worth 13,381,055. A second-largest stockholder of BCRX, Baker Bros. Advisors LP, holds 12,710,818 shares, controlling over 6.85% of the firm’s shares. BlackRock Fund Advisors is the third largest shareholder in BCRX, holding 12,105,777 shares or 6.52% stake. With a 3.94% stake in BCRX, the SPDR S&P Biotech ETF is the largest stakeholder. A total of 7,310,734 shares are owned by the mutual fund manager. The Vanguard Total Stock Market Index, which owns about 2.95% of BCRX stock, is the second-largest Mutual Fund holder. It holds 5,466,494 shares valued at 60.24 million. Fidelity Select Port. – Biotechno holds 2.26% of the stake in BCRX, owning 4,192,205 shares worth 46.2 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for BCRX since 12 analysts follow the stock currently. There are 5 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 7 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With BCRX analysts setting a high price target of $30.00 and a low target of $14.00, the average target price over the next 12 months is $18.60. Based on these targets, BCRX could surge 104.92% to reach the target high and fall by -4.37% to reach the target low. Reaching the average price target will result in a growth of 27.05% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. BCRX will report FY 2022 earnings on 02/28/2023. Analysts have provided yearly estimates in a range of -$0.89 being high and -$1.62 being low. For BCRX, this leads to a yearly average estimate of -$1.23. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. BioCryst Pharmaceuticals Inc. surprised analysts by $0.02 when it reported -$0.32 EPS against a consensus estimate of -$0.34. The surprise factor in the prior quarter was -$0.04. Based on analyst estimates, the high estimate for the next quarter is -$0.07 and the low estimate is -$0.45. The average estimate for the next quarter is thus -$0.27.
Summary of Insider Activity:
Insiders traded BCRX stock several times over the past three months with 15 Buys and 0 Sells. In these transactions, 146,449 shares were bought while 0 shares were sold. The number of buy transactions has increased to 58 while that of sell transactions has risen to 16 over the past year. The total number of shares bought during that period was 1,583,665 while 620,139 shares were sold.